Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H
À¶Ý®ÊÓƵ
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H O'Donnell, P. H., Hoimes, C. J., Rosenberg, J. E., Petrylak, D. P., Mar, N., Barata, P. C., Srinivas, S., Gourdin, T., Henry, E., Bilen, M., George, S., Rao, S., Assikis, V. J., Burgess, E. F., Lewis, B. E., Bowman, I., Brancato, S., Mildiner-Earley, S., Zhu, Y., Flaig, T. W. LIPPINCOTT WILLIAMS & WILKINS. 2024View details for